Top

Published in:

01-04-2013 | COMMENTARY

Screening, case finding or primary cancer prevention in the developing world?

Authors: Gustaf Edgren, Pagona Lagiou, Dimitrios Trichopoulos, Hans-Olov Adami

Published in: European Journal of Epidemiology | Issue 4/2013

Excerpt

On account of increasingly successful control of infectious diseases and improvements in both maternal and perinatal mortality, the relative contribution of cancer to the global burden of disease is growing. The 2008 World Cancer Report predicts that the annual number of cancer deaths in the world will have increased by 70–124 % until the year 2030 [1]. Because relative changes in longevity, a key driver of the total cancer burden, will likely be largest in the developing world, this dramatic increase will disproportionately affect low income countries. Unavoidably, the result will be added stress on healthcare systems that are facing the heavy burden of communicable diseases. …

Boyle P, Levin B, editors. World Cancer Report 2008. Lyon: International Agency for Research on Cancer (IARC); 2008.

Smith RA, Caleffi M, Albert US, et al. Breast cancer in limited-resource countries: early detection and access to care. Breast J. 2006;12(Suppl 1):S16–26. doi:10.1111/j.1075-122X.2006.00200.x.PubMedCrossRef

Ifere GO, Abebe F, Ananaba GA. Emergent trends in the reported incidence of prostate cancer in Nigeria. Clin Epidemiol. 2012;4:19–32. doi:10.2147/CLEP.S23536.PubMed

Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376(9747):1186–93. doi:10.1016/S0140-6736(10)61152-X.PubMedCrossRef

Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010;363(13):1203–10. doi:10.1056/NEJMoa1000727.PubMedCrossRef

Jørgensen KJ, Zahl PH, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ. 2010;340:c1241.PubMedCrossRef

Gotzsche PC, Jorgensen KJ, Zahl PH, Maehlen J. Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes Control. 2012;23(1):15–21. doi:10.1007/s10552-011-9867-8.PubMedCrossRef

Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13. doi:10.1093/jnci/djq099.PubMedCrossRef

Adami HO. The prostate cancer pseudo-epidemic. Acta Oncol. 2010;49(3):298–304. doi:10.3109/02841860903584945.PubMedCrossRef

10.

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol. 2011;29(4):464–7. doi:10.1200/JCO.2010.30.6373.PubMedCrossRef

11.

Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann intern med. 2011;155(11):762–71. doi:10.1059/0003-4819-155-11-201112060-00375.

12.

Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6 Suppl):273S–309S.PubMedCrossRef

13.

Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N Engl J Med. 1993;328(19):1365–71. doi:10.1056/NEJM199305133281901.PubMedCrossRef

14.

Bretthauer M, Kalager M. Colonoscopy as a triage screening test. N Engl J Med. 2012;366(8):759–60. doi:10.1056/NEJMe1114639.PubMedCrossRef

15.

Clarke EA, Anderson TW. Does screening by “Pap” smears help prevent cervical cancer? A case-control study. Lancet. 1979;2(8132):1–4.PubMedCrossRef

16.

Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8(5):755–63.PubMedCrossRef

17.

Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366(9499):1784–93.PubMedCrossRef

18.

Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. Lancet. 2011;377(9775):1438–47.PubMedCrossRef

19.

Chokshi DA, Farley TA. The cost-effectiveness of environmental approaches to disease prevention. N Engl J Med. 2012;367(4):295–7. doi:10.1056/NEJMp1206268.PubMedCrossRef

20.

Whitby LG. Screening for disease: definitions and criteria. Lancet. 1974;2(7884):819–22.PubMedCrossRef

21.

Ponten J, Adami HO, Bergstrom R, et al. Strategies for global control of cervical cancer. Int J Cancer. 1995;60(1):1–26.PubMedCrossRef

22.

Jemal A, Bray F, Forman D, et al. Cancer burden in Africa and opportunities for prevention. Cancer. 2012;. doi:10.1002/cncr.27410.

Title: Screening, case finding or primary cancer prevention in the developing world?
Authors: Gustaf Edgren
Pagona Lagiou
Dimitrios Trichopoulos
Hans-Olov Adami
Publication date: 01-04-2013
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 4/2013
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-013-9788-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Screening, case finding or primary cancer prevention in the developing world?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2013

Mediterranean diet and colorectal cancer risk: results from a European cohort

Gout and the risk of Parkinson’s disease in Denmark

Serum cystatin C and prediabetes in non-obese US adults

Dietary fibre and cardiovascular disease mortality in the UK Women’s Cohort Study

Time-dependent propensity score and collider-stratification bias: an example of beta2-agonist use and the risk of coronary heart disease

The role of milk protein in increasing risk of Parkinson’s disease